Rain Oncology Incis A Clinical Stage Biotechnology Company Based In Newarkcaliforniathe Company Specializes In Precision Oncology Therapies That Target Cancers With Clear Genetic Driversformerly Known As Rain Therapeutics Inc Rain Focuses On Selecting Patients For Its Therapies Based On Tumor Genetics Rather Than Histologyemploying A Tumor Agnostic Approach Rain Operates As A Subsidiary Of Pathos Aiincfollowing A Merger That Aims To Enhance Its Drug Development Capabilities Through Ai Driven Technologythe Company Is Advancing Its Pipeline With Therapies Like Milademetanan Oral Small Molecule Inhibitor Currently In Phase 3 Trials For Dedifferentiated Liposarcoma And Phase 2 Trials For Other Cancers With Mdm2 Amplificationadditionallyrain Is Developing A Rad52 Inhibitor Program Targeting Cancers With Homologous Recombination Deficiencies With A Strong Emphasis On Partnerships And Licensing Opportunitiesrain Is Committed To Delivering Targeted Therapies That Improve Patient Outcomes In Oncologythe Company Maintains A Robust Financial Position To Support Its Research And Development Efforts
No conferences found for this company.
| Company Name | Rain Pharma |
| Country |
Saudi Arabia
|
| Address | N/A |
| Telephone | N/A |
| N/A |
